ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
5 announcements with these filters
Q1FY27 revenue grew 26% to INR 2,150 Cr. Strategy focuses on US Generics volume growth, India Specialty therapeutic scale-up, and managing margin dilution from US branded investments.
Alembic Pharma delivered strong Q1 FY27 results with 26% revenue growth, driven by a 49% surge in US formulations. Strategy focuses on specialty US branded expansion and peptide development.
Alembic Pharma delivered Q4 FY26 revenue of ₹1,838 Cr (up 4% YoY) and PAT of ₹203 Cr. FY26 revenue grew 10% YoY to ₹6,201 Cr with 25% EBITDA margins before R&D.
Management showcases a 100-year legacy transitioning into a high-tech global pharmaceutical player through massive facility expansion and R&D focus.
Alembic Pharma reported Q4FY26 revenue of INR 18.48 Bn, up 4% YoY, and PAT of INR 2.03 Bn, up 29% YoY. The company launched its first branded product, Pivya, in the US.